Robert W. Holloway

Gynecologic Oncology | Oncology

2501 N Orange Ave Ste 786
Orlando, FL 32804

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 91 publications

Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer.

Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer.

Journal: Gynecologic oncology reports

Published: May 06, 2026

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 04, 2026

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.

Journal: Future oncology (London, England)

Published: December 12, 2025

Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].

Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].

Journal: Gynecologic oncology

Published: November 07, 2025

Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 13, 2025

Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer.

Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer.

Journal: JCO precision oncology

Published: September 24, 2025

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 11, 2025

A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer.

A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: July 03, 2025

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.

Journal: Gynecologic oncology

Published: April 08, 2025

Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours.

Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours.

Journal: Clinical and translational medicine

Published: April 04, 2025

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 04, 2025

Recurrence and survival in high-intermediate risk endometrial cancers with isolated tumor cell lymph node metastasis.

Recurrence and survival in high-intermediate risk endometrial cancers with isolated tumor cell lymph node metastasis.

Journal: Gynecologic oncology reports

Published: November 21, 2024

Showing 1-12 of 91

Last Updated: 09/26/2026